ADME studies of TUG-770 (a GPR-40 inhibitor agonist) for the treatment of type 2 diabetes using SwissADME predictor: In silico study
Khaldun M. Al Azzam, El-Sayed Negim, Hassan Y. Aboul-Enein
DOI: 10.7324/JAPS.2022.120418Pages: 159-169
ADME studies of TUG-770 (a GPR-40 inhibitor agonist) for the treatment of type 2 diabetes using SwissADME predictor: In silico study
Khaldun M. Al Azzam, El-Sayed Negim, Hassan Y. Aboul-Enein
DOI: 10.7324/JAPS.2022.120418Pages: 159-169